These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 6369278)

  • 1. Treatment response criteria for prostatic cancer.
    Schroeder FH
    Prostate; 1984; 5(2):181-91. PubMed ID: 6369278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of metastatic prostate cancer. An analysis of response criteria in patients with measurable soft tissue disease.
    Citrin DL; Elson P; DeWys WD
    Cancer; 1984 Jul; 54(1):13-7. PubMed ID: 6372984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group.
    Sylvester RJ; Denis L; de Voogt H
    Eur Urol; 1998; 33(2):134-43. PubMed ID: 9519354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Response criteria for prostatic cancer treated by chemotherapy or antiandrogenic therapy].
    Akaza H; Usami M; Kotake T; Matsumura Y; Moriyama N; Imai K; Fuse H; Isaka S; Yamanaka H; Matsumoto K
    Hinyokika Kiyo; 1987 Jun; 33(6):894-904. PubMed ID: 3673839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer.
    Takeuchi S; Arai K; Saitoh H; Yoshida K; Miura M
    J Urol; 1996 Nov; 156(5):1691-5. PubMed ID: 8863572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apples and oranges: building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials.
    Dawson NA
    J Clin Oncol; 1998 Oct; 16(10):3398-405. PubMed ID: 9779719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer: evaluation of response to treatment, response criteria, and the need for standardization of the reporting of results.
    Aabo K
    Eur J Cancer Clin Oncol; 1987 Feb; 23(2):231-6. PubMed ID: 3327696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center.
    Denis LJ; Keuppens F; Smith PH; Whelan P; de Moura JL; Newling D; Bono A; Sylvester R
    Eur Urol; 1998; 33(2):144-51. PubMed ID: 9519355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II evaluation of adriamycin and cis-platinum in hormone resistant prostate cancer.
    Citrin DL; Hogan TF
    Cancer; 1982 Jul; 50(2):201-6. PubMed ID: 7200827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative reliability of five serially measured markers for prognosis of progression in prostate cancer.
    Killian CS; Emrich LJ; Vargas FP; Yang N; Wang MC; Priore RL; Murphy GP; Chu TM
    J Natl Cancer Inst; 1986 Feb; 76(2):179-85. PubMed ID: 2418245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
    Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
    J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between extent of metastatic lesions in whole body bone scintigraphy of patients with prostatic cancer and prostatic acid phosphatase in serum with Eiken PAP RIA kit.
    Kida T; Higuchi Y
    Oncology; 1983; 40(5):346-50. PubMed ID: 6621997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of the combination of nilutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients).
    Bertagna C; De Géry A; Hucher M; François JP; Zanirato J
    Br J Urol; 1994 Apr; 73(4):396-402. PubMed ID: 8199827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center.
    Denis LJ; Carnelro de Moura JL; Bono A; Sylvester R; Whelan P; Newling D; Depauw M
    Urology; 1993 Aug; 42(2):119-29; discussion 129-30. PubMed ID: 8367920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen as a unique routine test in monitoring therapy for inoperable prostate cancer: comparison with radionuclide bone scan and prostatic acid phosphatase.
    Barichello M; Gion M; Bonazza A; Delli Ponti US; Bolgan A; Contemori GP; Barioli P; Capitanio G; Pecori B; Omacini S
    Eur Urol; 1995; 27(4):295-300. PubMed ID: 7544735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring of prostatic cancer by an enzyme-linked immunosorbent assay of serum prostatic acid phosphatase.
    Cooper EH; Pidcock NB; Daponte D; Glashan RW; Rowe E; Robinson MR
    Eur Urol; 1983; 9(1):17-23. PubMed ID: 6337053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer--Genitourinary Group Study 30853.
    Newling DW; Denis L; Vermeylen K
    Cancer; 1993 Dec; 72(12 Suppl):3793-8. PubMed ID: 8252492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II studies on prostate cancer.
    Schröder FH; Norming U; Blumenstein BA; Busch C; Van Glabbeke M; Høisaeter PA; Johansson JE; Tribukait B
    Urology; 1997 Apr; 49(4A Suppl):3-14. PubMed ID: 9111610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topometric, roentgenologic, laboratory and clinical criteria of tumor regression in conservative management of prostatic carcinoma.
    Korolchook V; Balter S
    Scand J Urol Nephrol Suppl; 1980; 55():75-81. PubMed ID: 6938040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.